START TYPING AND PRESS ENTER TO SEARCH ARTICLES

Active Clinical Trials

Study Title Targeted Patients Recruitment Status
A Long-term, Open-label Follow-up Study of Tasocitinib (CP-690,550) For Treatment of Rheumatoid Arthritis Patients with Rheumatoid Arthritis Closed
A clinical outcomes study to evaluate the effects of IL-6 receptor blockade with tocilizumab (TCZ) in comparison with etanercept (ETA) on the rate of ischemic cardiovascular events in patients with moderate to severe rheumatoid arthritis (RA). Patients with Rheumatoid Arthritis Closed
A 24-month, phase IV,randomized,double masked, multicenter study of ranibizumab monotherapy or ranibizumab in combination with verteporfin photodynamic therapy on visual outcome in patients with symptomatic macular polypoidal choroidal vasculopathy Patients with symptomatic macular polypoidal choroidal vasculopathy Closed

Completed Clinical Trials

Study Title Targeted Patients Study Status
An Asia Pacific non-randomized, open-label phase II study evaluating the safety and efficacy of FOLFIRI plus cetuximab (Erbitux) or FOLFOX plus cetuximab as first-line therapy in subjects with KRAS wild-type metastatic Colorectal cancer (APEC-Study) Patients with metastatic colorectal cancer Closed
Phase 3, Randomized, Double-Blind Study of the Efficacy and Safety of 2 Doses of CP-690,550 compared to Methotrexate in Methotrexate-Naïve Patients with Rheumatoid Arthritis Patients with Rheumatoid Arthritis Closed
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFa Monoclonal Antibody, Administered Intravenously, in Subjects with Active Rheumatoid Arthritis Despite Methotrexate Therapy Patients with Rheumatoid Arthritis Closed
A phase 2 randomized, double-blind assessment of efficacy and safety of PF-04171327 (1, 5, 10, 15mg dose, daily) Patients with Rheumatoid Arthritis Closed
A 24 week randomised, open label, 3 parallel-group comparison of once and twice daily biphasic insulin aspart (BIAsp) 30 plus sitagliptin and twice daily BIAsp 30, all in combination with metformin in insulin naïve type 2 diabetic subjects inadequately controlled on sitagliptin and metformin. Patients with Type 2 Diabetes Mellitus Closed
Efficacy and safety of agomelatine (25 mg/day with blinded potential adjustment to 50 mg/day) for 12 weeks in non-depressed out-patients with Generalized Anxiety Disorder. A 12-week randomised, double-blind, versus venlafaxine XR (75 mg/day with blinded potential adjustment up to 225 mg/day), 2-arm parallel groups, international multicenter study Patient with Generalized Anxiety Disorder Closed
A randomized, phase ii, placebo‑controlled study of gdc-0068, an inhibitor to akt, in combination with fluoropyrimidine plus oxaliplatin in patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma Patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma Closed




START TYPING AND PRESS ENTER TO SEARCH ARTICLES